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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of antibiotics for the secondary prevention of coronary heart disease.
As a secondary objective, we plan to assess the effects of individual types of antibiotics for the secondary prevention of coronary heart
disease.
B A C K G R O U N D
Description of the condition
Coronary heart disease is the collective term for a group of dis-
eases consisting of stable angina, unstable angina, myocardial in-
farction, and sudden cardiac death (Wong 2014). Coronary heart
disease is estimated to be the leading cause of death worldwide
(WHO 2011; WHO 2016), and 15.5 million people in the USA
alone suffer from coronary heart disease (Mozaffarian 2016). The
World Health Organization (WHO) has estimated that 7.4 mil-
lion people die each year globally because of coronary heart dis-
ease with over three quarters of the deaths occurring in low- and
middle-income countries (WHO 2011; WHO 2016). Coronary
heart disease also has a significant impact on healthcare costs and
accounts for approximately EUR 196 billion in Europe and USD
207.3 billion in the USA (Ferreira-Gonzalez 2014; Mozaffarian
2016).
The pathogenesis of coronary heart disease is related to the nar-
rowing or blockage of the coronary arteries supplying the heart
with blood. This process is usually caused by build-up of fatty
material and plaque in the walls of the coronary arteries leading
to atherosclerosis (Ross 1999; Libby 2010; Libby 2011; Ambrose
2015). Atherosclerosis is a chronic immune-mediated inflamma-
tory disease that usually develops over years, ultimately limiting
perfusion to the heart, which may cause shortages of oxygen and
glucose, leading to symptoms such as chest pain (angina) and
shortness of breath (Ross 1999; Ambrose 2015).
People with established coronary heart disease have a high risk of
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subsequent cardiovascular events including cardiovascular death,
myocardial infarction, and stroke (Smith 2011;WHO2011; Eckel
2014; Piepoli 2016). Therapeutic lifestyle changes (e.g. increased
physical activity; weight reduction; dietary modification; smok-
ing cessation; and alcohol intake reduction) and adjunctive drug
therapies (e.g. antithrombotic treatment; managing hypertension;
diabetes; dyslipidaemia; and chronic kidney disease) are neces-
sary to improve survival and quality of life, and reduce recurrent
events and the need for revascularisation procedures (Smith 2011;
WHO 2011; Eckel 2014; Piepoli 2016). Nonetheless, even com-
plete adherence to the before-mentioned therapies is reported to
not completely eliminate the person’s risk of subsequent cardio-
vascular events (Bertrand 2016). This residual risk may result, in
part, from the failure of current therapies to efficiently address
inflammation (Bertrand 2016).
Studies have shown that inflammation seems to be a predictor
for the development and progression of atherosclerosis (Libby
2002; Kaptoge 2010; Lawson 2016) and the inflammatory process
may be induced by stimuli from infectious agents (Mendall 1996;
Rosenfeld 2011; Lawson 2016). The infectious agents might in-
duce the inflammatory process by infecting vascular cells within
the atheromatous plaque and consequently activating an innate
immune response (Rosenfeld 2011). The activated innate immune
response then contributes to the inflammation within the plaque
(Rosenfeld 2011). Moreover, infectious agents may induce in-
flammation at non-vascular places, which might lead to increased
secretion of cytokines and other acute-phase proteins. The cy-
tokines and other acute-phase proteins then add to the inflamma-
tion within the plaque (Rosenfeld 2011). Hence, an association
between coronary heart disease and various infectious agents has
been suggested and a number of studies have investigated the va-
lidity of this possible association.
Chlamydia pneumoniae has been identified in atheromatous
plaques (Shor 1992; Kuo 1993; Muhlestein 1996; Assar 2015;
Pigarevskii 2015). Moreover, seroepidemiological studies (Saikku
1988; Thom 1991; Linnanmaki 1993; Kazar 2005; Romano
Carratelli 2006; Sakurai-Komada 2014) and a meta-analysis of
seroepidemiological studies (Danesh 1997) have all shown in-
creased levels of C pneumoniae antibodies in people with coro-
nary heart disease. In vivo studies and a meta-analysis of ob-
servational studies have shown that C pneumoniae may con-
tribute to atherosclerosis (Burnett 2001; Ezzahiri 2002; Ezzahiri
2003; Filardo 2015). Contrary to these findings, prospective
seroepidemiological studies (Ridker 1999;Danesh 2000a; Danesh
2000b; Danesh 2002), retrospective seroepidemiological studies
(Prasad 2002; Al-Younes 2016), andmeta-analyses of seroepidemi-
ological studies (Danesh 2000a; Danesh 2000b; Danesh 2002;
Bloemenkamp 2003) did not show any association between C
pneumoniae antibodies and coronary heart disease.
Porphyromonas gingivalis has also been identified in atheroma-
tous plaques (Pucar 2007; Zaremba 2007; Gaetti-Jardim 2009;
Mahendra 2009). Moreover, studies have shown increased lev-
els of antibodies or higher amount of oral bacterial burden of P
gingivalis in people with coronary heart disease (Pussinen 2004;
Renvert 2006; Gotsman 2007; Mahendra 2015). In vivo stud-
ies have shown that P gingivalismay contribute to atherosclerosis
(Brodala 2005; Maekawa 2011). Contrary to these findings, ret-
rospective studies (Spahr 2006; Pesonen 2009; Andriankaja 2011)
and a prospective study (De Boer 2014) did not show any associ-
ation between P gingivalis and coronary heart disease.
Helicobacter pylori is another infectious agent that might induce an
inflammatory process and lead to coronary heart disease. The as-
sociation between coronary heart disease andH pylori has been as-
sessed in seroepidemiological studies (Mendall 1994; Lenzi 2006;
Vcev 2007; Shmuely 2014; Matusiak 2016), a meta-analysis of
seroepidemiological studies (Danesh 1997), and meta-analyses of
prospective studies (Sun 2016; Jiang 2017). These studies have
shown that infection with H pylori increases the risk of coro-
nary heart disease. Contrary to these findings, prospective studies
(Whincup 1996; Folsom 1998; Roivainen 2000; Zhu 2001; Zhu
2002; Jin 2007) and a meta-analysis of seroepidemiological stud-
ies (Danesh 1998) did not show any association between H pylori
and coronary heart disease.
A possible association between Escherichia coli and cardiovascular
disease has been assessed. However, a cohort study has shown that
infection with E coli did not increase the risk of cardiovascular dis-
ease in the decade following infection (Hizo-Abes 2013). Further,
a seroepidemiological study did not show any association between
E coli and coronary heart disease (Mahdi 2002).
Description of the intervention
Antibiotics are antimicrobial drugs of chemical origin that treat
and prevent bacterial infections by either killing or inhibiting the
growth of the bacteria (Waksman 1947). Antibiotics can be clas-
sified based on their mechanism of action (bactericidal or bac-
teriostatic), bacterial spectrum (broad or narrow) and chemical
structure (e.g. penicillins,macrolides, quinolones, or tetracyclines)
(Berdy 2005). The optimal dose and duration of antibiotic ther-
apy depends on various factors (e.g. the patient’s immune status,
the infecting agent, and the focus of infection) (Polk 1999).
Macrolides, such as azithromycin, clarithromycin, and ery-
thromycin, have been the primary antibiotic class used to inves-
tigate the effects of antibiotics as secondary prevention in people
with coronary heart disease, presumably because C pneumoniae
and H pylori are known to be sensitive to macrolides (Chirgwin
1989;Malfertheiner 2007). Macrolides’ mechanism of action is to
inhibit the protein synthesis through binding to the 50S subunit of
the ribosome (Gaynor 2003). However, the use of macrolides has
been reported in both observational studies and in a randomised
clinical trial to increase the risk of cardiovascular morbidity and
mortality (see Why it is important to do this review). The in-
creased risk of cardiovascular morbidity and mortality might be
associated with macrolides’ pro-arrhythmic effects (i.e. QT pro-
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longation) leading to torsades de pointes (Bril 2010). Further, the
use of macrolides might lead to an inflammatory cascade result-
ing in more vulnerable plaques that over time increases the risk of
plaque rupture and, hence, leads to increased risk of cardiovascular
events and mortality (Winkel 2011).
How the intervention might work
Antibiotics might prevent the development of coronary heart dis-
ease through antibacterial activity. In addition, animal studies
and in-vitro studies suggest that several classes of antibiotics (e.g.
macrolides, tetracyclines, or quinolones) seem to exert anti-in-
flammatory and anti-oxidative effects, which might slow down the
atherogenesis independently of any antibacterial effect (Anderson
1996; Rajagopalan 1996; Dalhoff 2003; Sapadin 2006; Steel
2012). The anti-inflammatory and anti-oxidative effects might
stabilise the atherosclerotic plaques.
Why it is important to do this review
Coronary heart disease is the leading cause of death worldwide as it
leads to 7.4 million deaths each year (WHO 2011; WHO 2016).
People with established coronary heart disease have a high risk of
subsequent cardiovascular events including cardiovascular death,
myocardial infarction, and stroke (Smith 2011;WHO2011; Eckel
2014; Piepoli 2016). Prevention and management of the common
risk factors for coronary heart disease is necessary to improve sur-
vival and quality of life, and reduce recurrent events and the need
for revascularisation procedures (Smith 2011; WHO 2011; Eckel
2014; Piepoli 2016). Nonetheless, even complete adherence to
the before-mentioned therapies may not completely eliminate the
person’s risk of subsequent cardiovascular events (Bertrand 2016).
The use of antibiotics might play a possible part in the preventive
efforts of people with coronary heart disease, and might improve
survival and quality of life, and reduce recurrent events and the
need for revascularisation procedures.
The use of antibiotics for secondary prevention of coronary heart
disease is not mentioned in any guidelines, indicating that it is not
conventional therapy (Fihn 2012; Montalescot 2013). However,
a very large number of people with coronary heart disease receive
antibiotics each year to treat proven or suspected bacterial infec-
tions. In the first instance, the antibiotics may help them. In the
second instance, any adverse event may be as likely as any bene-
fits. In both instances, we need to know the impact of antibiotic
intervention on long-term health.
The first trials that investigated the use of antibiotics for secondary
prevention of coronary heart disease were published in the late
1990s. The trials compared macrolide versus placebo in people
with coronary heart disease. The trials showed conflicting results
and made clear the need for larger trials (Gupta 1997; Anderson
1999; Torgano 1999; Gurfinkel 1999).
Several meta-analyses of randomised trials have assessed the ef-
fects of antibiotics for secondary prevention of coronary heart dis-
ease (Etminan 2004; Andraws 2005; Baker 2007; Gluud 2008).
Etminan 2004 included nine trials with 12,032 participants;
Andraws 2005 included 11 trials with 19,217 participants; and
Baker 2007 included six trialswith 13,778participants. All of these
reviews compared antibiotics versus placebo. None of the reviews
showed any benefits or harms of antibiotic therapy for secondary
prevention of coronary heart disease. Gluud 2008 included 17 tri-
als with 25,271 participants comparing antibiotics versus placebo,
and found a significantly increased risk of all-cause mortality of
10% in the antibiotic group. Moreover, Gluud 2008 did a meta-
analysis of the three trials that reported more than two years’ fol-
low-up (i.e. PROVE-IT (Cannon 2005), ACES (Grayston 2005),
and CLARICOR (Gluud 2008)) and showed a significantly in-
creased risk of all-cause mortality of 17% in the antibiotic group.
Cheng 2015 recently included 33 studies of various designs with
20,779,963 participants in a review comparing macrolides with
or to placebo or no intervention. The review included any type
of participant and did not focus on a specific infectious agent
or disease. The authors of the review found no significant effect
of macrolides on all-cause mortality. However, the participants
treated with macrolide had a significantly (152%) higher risk of
sudden death from cardiac problems and 31% had a higher risk
of dying from cardiovascular problems.
Currently, no guidelines report whether antibiotics should be used
or avoided as secondary prevention of coronary heart disease (Fihn
2012; Montalescot 2013). This might be because the use of an-
tibiotic therapy for secondary prevention of coronary heart disease
lost momentum a decade ago, possibly as a consequence of the
majority of previous evidence showing no effects - either benefi-
cial or harmful. Nevertheless, the public-health aspect of admin-
istration of antibiotics to people with coronary heart disease is
not to be neglected. Further, our preliminary literature search has
identified several new trials that were not included in the former
attempts to systematically review the literature, and more trials
may be identified during the literature search. Accordingly, the
benefits and harms of antibiotics in people with coronary heart
disease seem unclear based on current evidence. Furthermore, an-
tibiotics, including macrolide, are commonly used interventions
in people with coronary heart disease and any beneficial or harm-
ful effects of administering antibiotics in this group of people is
of urgent importance. The CLARICOR trial, as mentioned pre-
viously, showed that clarithromycin versus placebo for secondary
prevention of coronary heart disease significantly increased the risk
of death (Jespersen 2006; Gluud 2008; Winkel 2015). We, there-
fore, find it very important to investigate whether antibiotics have
a beneficial, neutral, or harmful effect for secondary prevention of
coronary heart disease.
No former relevant review has taken into account both risks of
random errors and risk of systematic errors (Cochrane method-
ology, Trial Sequential Analysis (TSA), and GRADE assessment)
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(Wetterslev 2008; Keus 2010; Higgins 2011a; Jakobsen 2014).
Therefore, it is still unclear whether antibiotics have a beneficial,
neutral, or harmful effect for secondary prevention of coronary
heart disease.
O B J E C T I V E S
To assess the beneficial and harmful effects of antibiotics for the
secondary prevention of coronary heart disease.
As a secondary objective, we plan to assess the effects of individual
types of antibiotics for the secondary prevention of coronary heart
disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of trial design, setting,
blinding, publication status, publication year, and language. We
will not include quasi-randomised trials and observational studies
for the assessment of harms. By focusing on randomised clinical
trials, we are aware that the present review will be biased towards
focusing on more benefits and less on harms.
Types of participants
Participants with any diagnosis of coronary heart disease, that is,
acute myocardial infarction, previous myocardial infarction, stable
angina, or unstable angina. We will accept the definitions used by
the individual trialists. We will include participants irrespective of
age, sex, and antibody status (e.g. for C pneumoniae, H pylori, P
gingivalis, or E coli). We will exclude participants with any other
cause of chronic inflammatory disease (e.g. lupus erythematosus,
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis,
polymyositis/dermatomyositis, and inflammatory bowel disease).
We will only include trials that include a subset of eligible partic-
ipants if separate data for the eligible participants are available or
if the majority of participants (i.e. more than 80%) are eligible.
We will document difficult decisions in the review, and sensitivity
analyses will assess the impact of these decisions on the review’s
findings.
Types of interventions
We will include three types of comparisons:
• antibiotic compared with placebo;
• antibiotic compared with no intervention (including no
placebo tablet); and
• antibiotic added to a co-intervention compared with a
similar co-intervention.
We will accept any type of antibiotic (e.g. azithromycin, clar-
ithromycin, erythromycin, doxycycline, tetracycline hydrochlo-
ride, gatifloxacin, levofloxacin, moxifloxacin, telithromycin, peni-
cillin, amoxicillin, or metronidazole) as the experimental inter-
vention, irrespective of dose, route of administration, or duration.
We will assess the effects of the individual types of antibiotics in
subgroup analyses.
We will accept any type of co-intervention when such co-inter-
vention is intended to be delivered similarly to the experimental
and the control group. We will assume that the effects of the co-
interventions will ’even out’ in both groups so that the possible
effects of the antibiotic will be reflected in the results. We will
do a check of co-interventions after randomisation in both inter-
vention groups and consider any major differences in our con-
clusions. As optimal medical therapy plays an important role for
the secondary prevention of coronary heart disease, we will per-
form a sensitivity analysis excluding trials with sub-optimal med-
ical therapy. Optimal medical therapy indicates at least one drug
for angina/ischaemic relief (e.g. short-acting nitrates, beta block-
ers, and calcium channel blockers) plus drugs for event prevention
(e.g. aspirin, clopidogrel, statins, ACE inhibitors, and angiotensin
receptor blockers) (Montalescot 2013).
Types of outcome measures
For all outcomes we will use the trial results at maximal follow-
up. However, if the trialists report results at multiple time points,
we will also assess the results reported at the time point closest to
24 months (plus and minus six months).
We chose 24 months’ follow-up based on the Kaplan-Meier curve
made by Winkel 2015. We believe that 24 months’ follow-up is
long enough to show any possible secondary prevention effects
of antibiotics. Furthermore, 24 months’ follow-up is not so long
that other factors, unrelated to the given trial but affecting the
outcomes, might decrease the statistical power, that is, that the
results are ’diluted’ by events unrelated to the trial.
Primary outcomes
• All-cause mortality
• Serious adverse event. We will define a serious adverse event
as any untoward medical occurrence that resulted in death; was
life-threatening; required hospitalisation or prolongation of
existing hospitalisation; resulted in persistent or significant
disability; or jeopardised the patient (ICH-GCP 1997).
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• Quality of life measured on any valid scale
Secondary outcomes
Definitions for secondary outcomes will be according to the indi-
vidual trialists.
• Cardiovascular mortality
• Myocardial infarction
• Stroke
• Sudden cardiac death
We will include randomised clinical trials irrespective of whether
they report the above outcomes.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, LILACS, Science Citation
Index Expanded on Web of Science and BIOSIS in order to iden-
tify relevant trials. The preliminary search strategy for MEDLINE
(Ovid) is given in Appendix 1 and will be adapted for use in the
other databases. We will apply the Cochrane sensitivity-maximis-
ing randomised clinical trial filter (Lefebvre 2011) to MEDLINE
(Ovid) and adaptations of it to the other databases, except CEN-
TRAL.
We will search all databases from their inception to the present
and we will impose no restriction on language of publication or
publication status. We will assess non-English language papers by
asking individuals that fluently speak the language for help. We
will not perform a separate search for adverse effects of antibiotics
used for the treatment of coronary heart disease. We will only
consider adverse effects described in the included trials.
Searching other resources
The reference lists of included randomised clinical trials, previous
systematic reviews, and other kinds of reviews will be checked for
any unidentified randomised clinical trials.Wewill contact authors
of included randomised clinical trials for further information and
we will contact the following major pharmaceutical companies by
email asking them for any unpublished randomised clinical trials:
• Merck & Co.;
• Roche Holding AG;
• Pfizer Inc.;
• Novartis AG;
• GlaxoSmithKline Plc;
• AstraZeneca Plc;
• Bristol-Myers Squibb Co.;
• Sanofi-Aventis;
• Abbott Laboratories;
• Taisho Pharmaceutical; and
• Pliva.
Furthermore, we will search for ongoing and unidentified ran-
domised clinical trials on:
• Google Scholar;
• The Turning Research into Practive (TRIP) Database;
• ClinicalTrials.gov;
• EU Clinical Trial Register;
• Chinese Clinical Trial Registry (ChCTR);
• International Standard Randomised Controlled Trial
Number (ISRCTN) registry;
• GSK Clinical Study Register;
• Pan African Clinical Trials Registry (PACTR);
• Australian New Zealand Clinical Trials Registry
(ANZCTR);
• Clinical Trials Registry - India (CTRI); and
• the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal.
We will also examine relevant retraction statements and errata for
included trials.
Data collection and analysis
We will follow Cochrane recommendations to perform the review
(Higgins 2011a) and we will use Review Manager 5 (RevMan 5)
to perform the analyses (RevMan 2014) and TSA (TSA 2011).
Selection of studies
Two authors (NJS, SS) will independently screen titles and ab-
stracts. We will retrieve all relevant full-text study reports/publica-
tions and two review authors (NJS, SS) will independently screen
the full text and identify and record reasons for exclusion of the
ineligible studies. We will resolve disagreements through discus-
sion or, if required, by consulting with a third author (JCJ). We
will display trial selection in a flow diagram as per the PRISMA
statement (Moher 2009).
We will record the selection process in sufficient detail to complete
a PRISMA flow diagram and ’Characteristics of excluded studies’
table.
Data extraction and management
Three authors (NJS, SS, SKK) will extract data independently
from included trials. We will resolve any disagreements by discus-
sion with a fourth author (JCJ). We will assess duplicate publica-
tions and companion papers of a trial together in order to eval-
uate all available data simultaneously (maximise data extraction,
correct bias assessment). We will contact the authors of the trials
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by email to specify any of the data, had they not been reported
sufficiently in the publication.
Trial characteristics
Bias risk components (as defined below); trial design (parallel, fac-
torial, or cross-over); number of intervention arms; length of fol-
low-up; estimation of sample size; inclusion and exclusion criteria.
Participant characteristics and diagnosis
Number of randomised participants; number of analysed partici-
pants; number of participants lost to follow-up/withdrawals/cross
over; age range (mean or median) and sex ratio; presence of cardio-
vascular risk factors (i.e. diabetes mellitus, hypertension, hyperlip-
idaemia, or smoking); antibody status (i.e. for C pneumoniae, H
pylori, P gingivalis, or E coli).
Intervention characteristics
Type of antibiotic; dose of antibiotic; duration of antibiotic ther-
apy; and mode of administration.
Control characteristics
Placebo or no-intervention.
Co-intervention characteristics
Type of co-intervention; dose of co-intervention; duration of co-
intervention; and mode of administration.
Outcomes
We will extract all outcomes listed above from each randomised
clinical trial, andwewill identifywhether outcomes are incomplete
or selectively reported according to the criteria described in Table
1.
Notes
We will extract details on funding of the trial and notable conflicts
of interest of trial authors, if available.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way. Two review au-
thors (NJS, SS) will independently transfer data into the RevMan
5 file (RevMan 2014). We will resolve any disagreements through
discussion or, if required, by consulting a third author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2017) in our evalua-
tion of the methodology and hence the risk of bias of the included
trials. We will evaluate the methodology in respect of:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other risks of bias;
• overall risk of bias.
These domains enable classification of randomised trials with low
risk of bias and high risk of bias. The latter trials tend to overes-
timate positive intervention effects (benefits) and underestimate
negative effects (harms) (Schulz 1995; Moher 1998; Kjaergard
2001; Gluud 2006; Wood 2008; Savovic 2012; Lundh 2017).
We will classify the trials according to the criteria described in
Table 1.
We will assess the domains ’blinding of outcome assessment’, ’in-
complete outcome data’, and ’selective outcome reporting’ for each
outcome result. Thus, we will be able to assess the bias risk for
each outcome assessed in addition to each trial.
Assesment of bias in conducting the systematic review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios (RRs) with 95% confidence interval
(CI) for dichotomous outcomes, as well as the TSA-adjusted CIs
(see below).
Continuous outcomes
Wewill calculate themean differences (MDs) and the standardised
mean difference (SMD) with 95% CI for continuous outcomes,
as well as the TSA-adjusted CIs (see below).
Wewill consider using the SMDapproach when all the trials assess
the same outcome but measure it in a variety of ways, but only as
a hypothesis-generating analysis (Deeks 2017).
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Unit of analysis issues
We will only include randomised clinical trials. For trials using
cross-over design, we will only include data from the first period
(Elbourne 2002; Deeks 2017). There will, therefore, not be any
unit of analysis issues.
Dealing with missing data
Wewill, as a first option, contact all trial authors to obtain missing
data (i.e. for data extraction and for assessment of risk of bias, as
specified above).
Dichotomous outcomes
Wewill not imputemissing values for any outcomes in our primary
analysis. In two of our sensitivity analyses (see paragraph below),
we will impute data.
Continuous outcomes
We will primarily analyse scores assessed at single time points. If
only change from baseline scores are reported, we will analyse the
results together with follow-up scores (Higgins 2011b). If standard
deviations (SDs) are not reported, we will calculate the SDs using
trial data if possible. We will not use intention-to-treat data if the
original report did not contain such data. We will not impute
missing values for any outcomes in our primary analysis. In two
of our sensitivity analyses (see paragraph below), we will impute
data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually assess any sign
of heterogeneity. We will secondly assess the presence of statisti-
cal heterogeneity by Chi2 test (threshold P < 0.10) and measure
the quantities of heterogeneity by the I2 statistic (Higgins 2002;
Higgins 2003).
Wewill follow the recommendations for thresholds in theCochrane
Handbook for Systematic Reviews of Interventions (Deeks 2017):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90% may represent substantial heterogeneity;
• 75% to 100%: may represent considerable heterogeneity.
We will investigate possible heterogeneity through subgroup anal-
yses. Ultimately, we may decide that a meta-analysis should be
avoided (Deeks 2017).
Assessment of reporting biases
Wewill use a funnel plot to assess reporting bias if we include 10 or
more trials.Wewill visually inspect funnel plots to assess the risk of
bias. We are aware of the limitations of a funnel plot (i.e. a funnel
plot assesses bias due to small sample size. From this information,
we will assess possible reporting bias). For dichotomous outcomes,
we will test asymmetry with the Harbord test (Harbord 2006).
For continuous outcomes, we will use the regression asymmetry
test (Egger 1997) and the adjusted rank correlation (Begg 1994).
Data synthesis
Meta-analysis
We will undertake this meta-analysis according to the recommen-
dations stated in the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2017), by Keus and colleagues (Keus 2010),
and according to the eight-step assessment suggested by Jakobsen
and colleagues (Jakobsen 2014). We will use the Cochrane statis-
tical software RevMan 5 (RevMan 2014) to analyse data.
We will assess our intervention effects with both random-effects
meta-analyses (DerSimonian 1986) and fixed-effect meta-analy-
ses (DeMets 1987). We will use the more conservative point es-
timate of the two (Jakobsen 2014). The more conservative point
estimate is the estimate closest to zero effect. If the two estimates
are similar, we will use the estimate with the widest CI. We will
conduct sensitivity analyses and subgroup analyses to explore the
reasons for substantial statistical heterogeneity (see Assessment of
heterogeneity). We will assess the risk of publication bias in meta-
analyses consisting of 10 trials or more by visual inspection of
funnel plots and statistical tests for funnel plot asymmetry (see
Assessment of reporting biases). We will adjust our thresholds for
statistical significance when there are problems with multiplic-
ity (family-wise error rate), by dividing the pre-specified P value
threshold with the value halfway between 1 (no adjustment) and
the number of primary or secondary outcome comparisons (Bon-
ferroni adjustment) (Jakobsen 2014; Jakobsen 2016). There are
three primary outcomes in this review, therefore, we will consider
a P value of 0.025 or less as the threshold for statistical significance
for these outcomes (Jakobsen 2014), and there are four secondary
outcomes, therefore, wewill consider a P value of 0.02 or less as the
threshold for statistical significance for these outcomes (Jakobsen
2014; Jakobsen 2016). We will use the eight-step procedure to as-
sess whether the thresholds for significance are crossed (Jakobsen
2014). We will include all trials in our analyses and conduct a sen-
sitivity analysis excluding trials with high risk of bias. If the results
are similar, we will base our primary conclusions on the overall
analysis. If they differ, we will base our primary conclusions on
trials at low risk of bias.
Where multiple trial intervention groups are reported in a single
trial, we will include only the relevant groups. If two comparisons
are combined in the same meta-analysis, we will halve the control
group to avoid double-counting (Deeks 2017).
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Trial Sequential Analysis
Cumulative meta-analyses are at risk of producing random errors
due to sparse data and multiple testing of accumulating data (Brok
2008; Wetterslev 2008; Brok 2009; Thorlund 2009; Wetterslev
2009; Thorlund 2010; Thorlund 2011; TSA 2011; Imberger
2015; Imberger 2016; Wetterslev 2017), therefore, TSA (TSA
2011) can be applied to control these risks (www.ctu.dk/tsa/)
(Thorlund 2011). Similar to a sample size calculation in a ran-
domised clinical trial, TSA calculates the required information size
(that is, the number of participants needed in a meta-analysis to
detect or reject a certain intervention effect) in order to minimise
random errors (Wetterslev 2009). The required information size
takes into account the anticipated intervention effect, the variance
of the anticipated difference in intervention effects, the acceptable
risk of falsely rejecting the null hypothesis (alpha), the acceptable
risk of falsely confirming the null hypothesis (beta), and the vari-
ance of the intervention effect estimates between trials (Wetterslev
2009; Turner 2013; Jakobsen 2014). To determine and predefine
the anticipated intervention effects, we searched for suitable em-
pirical data (Jakobsen 2014). However, no suitable data could be
found. Instead, we pragmatically hypothesise the anticipated in-
tervention effects:
• When analysing dichotomous outcomes, we pragmatically
anticipate an intervention effect equal to a relative risk reduction
of 15%.
• When analysing continuous outcomes, we pragmatically
anticipate an intervention effect equal to the mean difference of
the observed SD/2 (Norman 2003).
TSA enables testing for significance to be conducted each time
a new trial is included in the meta-analysis. On the basis of the
required information size, trial sequential monitoring boundaries
are constructed. This enables one to determine the statistical infer-
ence concerning cumulative meta-analysis that has not yet reached
the diversity-adjusted required information size (Wetterslev 2008;
Wetterslev 2009).
Firm evidence for benefit or harm may be established if a trial
sequential monitoring boundary is crossed before reaching the di-
versity-adjusted required information size, in which case further
trials may turn out to be superfluous. In contrast, if a boundary
is not surpassed one may conclude that it is necessary to continue
with further trials before a certain intervention effect can be de-
tected or rejected. Firm evidence for lack of the postulated inter-
vention effect can also be assessed with TSA. This occurs when
the cumulative Z-score crosses the trial sequential boundaries for
futility.
For dichotomous outcomes, we will estimate the required infor-
mation size based on a relative risk reduction of 15%, the observed
proportion of participants with an outcome in the control group,
an alpha of 2.5% for our primary outcomes and 2.0% for our sec-
ondary outcomes (see ’Meta-analysis’ above), a beta of 10%, and
diversity as suggested by the trials in the meta-analysis (diversity-
adjusted required information size) (Wetterslev 2009; Jakobsen
2014). In case there is some evidence or effect of the intervention,
a supplementary TSA will use the limit of the CI closest to 1.00 as
the anticipated intervention effect (Jakobsen 2014). Additionally,
we will calculate TSA-adjusted CIs.
For continuous outcomes, we will estimate the required informa-
tion size based on a minimal clinically important difference of
SD/2, the standard deviation observed in the control group, an
alpha of 2.5% for our primary outcomes and 2.0% for our sec-
ondary outcomes (see ’Meta-analysis’ above), a beta of 10%, and a
diversity as suggested by the trials in the meta-analysis (diversity-
adjusted required information size) (Wetterslev 2009; Jakobsen
2014). In case there is some evidence of effect of the intervention,
a supplementary TSA will use the limit of the CI closest to 0.00 as
the anticipated intervention effect (Jakobsen 2014). Additionally,
we will calculate TSA-adjusted CIs.
Subgroup analysis and investigation of heterogeneity
We will perform the following subgroup analyses when assessing
each outcome (all-cause mortality, serious adverse event, quality
of life, cardiovascular mortality, myocardial infarction, stroke, and
sudden cardiac death) both at the time point closest to 24 months’
follow-up and at maximal follow-up.
• Comparison of the effects between trials with different
types of antibiotic (e.g. azithromycin, clarithromycin,
erythromycin, doxycycline, tetracycline hydrochloride,
gatifloxacin, levofloxacin, moxifloxacin, telithromycin,
penicillin, amoxicillin, or metronidazole).
• Antibody status (i.e. people with identified C pneumoniae,
H pylori, P gingivalis, orE coli antibodies compared to people
without any identified C pneumoniae, H pylori, P gingivalis, orE
coli antibodies).
• Comparison of participants on statins at entry compared to
participants not on statins at entry (Jensen 2010).
• Comparison of the mean age of participants (0 to 59 years,
60 to 79 years, 80 years and over).
• Comparison of the effects between trials with different
clinical trial registration status (pre-registration, post-registration
or no registration).
Additionally, we will perform the following subgroup analysis
when assessing each outcome (all-cause mortality, serious adverse
event, quality of life, cardiovascular mortality, myocardial infarc-
tion, stroke, and sudden cardiac death) at maximal follow-up.
• Comparison of trials with less than 12 months’ follow-up
with trials equal to or longer than 12 months’ follow-up.
We will use the formal test for subgroup differences in RevMan 5
(RevMan 2014).
Sensitivity analysis
To assess the potential impact of bias, we will perform a sensitivity
analysis in which we exclude trials at overall high risk of bias.
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To assess the potential impact of themissing data for dichotomous
outcomes, we will perform the following four sensitivity analyses
when assessing each dichotomous outcome (all-cause mortality,
serious adverse event, cardiovascular mortality, myocardial infarc-
tion, stroke, and sudden cardiac death).
• ’Best-worst-case’ scenario: we will assume that all
participants lost to follow-up in the experimental group have
survived, had no serious adverse event, had no cardiovascular
death, had no myocardial infarction, had no stroke, and had no
sudden cardiac death; and all those participants lost to follow-up
in the control group have not survived, had a serious adverse
event, had a cardiovascular death, had a myocardial infarction,
had a stroke, and had a sudden cardiac death.
• ’Worst-best-case’ scenario: we will assume that all
participants lost to follow-up in the experimental group have not
survived, had a serious adverse event, had a cardiovascular death,
had a myocardial infarction, had a stroke, and had a sudden
cardiac death; and that all those participants lost to follow-up in
the control group have survived, had no serious adverse event,
had no cardiovascular death, had no myocardial infarction, had
no stroke, and had no sudden cardiac death.
• A modified ’best-worst-case’ scenario: we will assume that
half of the participants lost to follow-up in the experimental
group have survived, had no serious adverse event, had no
cardiovascular death, had no myocardial infarction, had no
stroke, and had no sudden cardiac death; and that half of the
participants lost to follow-up in the control group have not
survived, had a serious adverse event, had a cardiovascular death,
had a myocardial infarction, had a stroke, and had a sudden
cardiac death.
• A modified ’worst-best-case’ scenario: we will assume that
half of the participants lost to follow-up in the experimental
group have not survived, had a serious adverse event, had a
cardiovascular death, had a myocardial infarction, had a stroke,
and had a sudden cardiac death; and that half of the participants
lost to follow-up in the control group have survived, had no
serious adverse event, had no cardiovascular death, had no
myocardial infarction, had no stroke, and had no sudden cardiac
death.
We will present results of all four scenarios in our review.
When analysing quality of life, a ‘beneficial outcome’ will be the
group mean plus two standard deviations (SDs) (we will then use
one SD in another sensitivity analysis) of the group mean, and a
‘harmful outcome’ will be the group mean minus two SDs (we
will then use one SD in another sensitivity analysis) of the group
mean (Jakobsen 2014).
To assess the potential impact of missing SDs for continuous out-
comes, we will perform the following sensitivity analysis.
• Where SDs are missing and it is not possible to calculate
them, we will impute SDs from trials with similar populations
and low risk of bias. If we find no such trials, we will impute SDs
from trials with a similar population. As the final option, we will
impute SDs from all trials.
We will present results of this scenario in our review.
Other post-hoc sensitivity analyses might be warranted if unex-
pected clinical or statistical heterogeneity is identified during the
analysis of the review results (Jakobsen 2014).
’Summary of Findings’ table
We will create a Summary of Findings table using each of the
primary (all-cause mortality, serious adverse event, and quality
of life) and secondary outcomes (cardiovascular mortality, my-
ocardial infarction, stroke, and sudden cardiac death). We will
use the five GRADE considerations (trial limitations, consistency
of effect, imprecision, indirectness, and publication bias) to as-
sess the quality of a body of evidence as it relates to the stud-
ies that contribute data to the meta-analyses for the prespeci-
fied outcomes (Schunemann 2003; Guyatt 2008; Guyatt 2011;
Jakobsen 2014). We will use methods and recommendations de-
scribed in chapter 8 (Section 8.5) (Higgins 2011b) and Chapter
12 (Schünemann 2017) of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a) using GRADEpro GDT
software (GRADEpro GDT 2015; Schunemann 2013). We will
justify all decisions to downgrade the quality of studies using foot-
notes and we will make comments to aid the reader’s understand-
ing of the review where necessary.
We will include all trials in our analyses, and conduct a sensitivity
analysis excluding trials at high risk of bias. If the results are similar,
wewill base our primary ’Summary of Findings’ tables andprimary
conclusions on the overall analysis. If they differ, we will base our
primary ’Summary of Findings’ tables and primary conclusions on
trials at low risk of bias.
A C K N OW L E D G E M E N T S
We thank Cochrane Heart for their expert assistance in creating
the search strategy and the provision of a template protocol.
9Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Al-Younes 2016
Al-Younes HM, Abu Abeeleh MA, Jaber BM. Lack of strong
association of Chlamydia pneumoniae and atherosclerosis
in a Jordanian population. Journal of Infection in Developing
Countries 2016;10(5):457–64.
Ambrose 2015
Ambrose JA, Singh M. Pathophysiology of coronary artery
disease leading to acute coronary syndromes. F1000Prime
Reports 2015;7:08.
Anderson 1996
Anderson R, Theron AJ, Feldman C. Membrane-stabilizing,
anti-inflammatory interactions of macrolides with human
neutrophils. Inflammation 1996;20(6):693–705.
Anderson 1999
Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S,
Nielson C, et al. Randomized secondary prevention trial of
azithromycin in patients with coronary artery disease and
serological evidence for Chlamydia pneumoniae infection:
The Azithromycin in Coronary Artery Disease: Elimination
of Myocardial Infection with Chlamydia (ACADEMIC)
study. Circulation 1999;99(12):1540–7.
Andraws 2005
Andraws R, Berger JS, Brown DL. Effects of antibiotic
therapy on outcomes of patients with coronary artery
disease: a meta-analysis of randomized controlled trials.
JAMA 2005;293(21):2641–7.
Andriankaja 2011
Andriankaja O, Trevisan M, Falkner K, Dorn J, Hovey
K, Sarikonda S, et al. Association between periodontal
pathogens and risk of nonfatal myocardial infarction.
Community Dentistry and Oral Epidemiology 2011;39(2):
177–85.
Assar 2015
Assar O, Nejatizadeh A, Dehghan F, Kargar M, Zolghadri
N. Association of Chlamydia pneumoniae infection with
atherosclerotic plaque formation. Global Journal of Health
Science 2015;8(4):260–7.
Baker 2007
Baker WL, Couch KA. Azithromycin for the secondary
prevention of coronary artery disease: a meta-analysis.
American Journal of Health-System Pharmacy 2007;64(8):
830–6.
Begg 1994
Begg CB, Mazumdar M. Operating characteristics of a rank
correlation test for publication bias. Biometrics 1994;50(4):
1088–101.
Berdy 2005
Berdy J. Bioactive microbial metabolites. The Journal of
Antibiotics 2005;58(1):1–26.
Bertrand 2016
Bertrand MJ, Tardif JC. Inflammation and beyond: new
directions and emerging drugs for treating atherosclerosis.
Expert Opinion on Emerging Drugs 2016;22(1):1–26.
Bloemenkamp 2003
Bloemenkamp DG, Mali WP, Visseren FL, Van der Graaf Y.
Meta-analysis of sero-epidemiologic studies of the relation
between Chlamydia pneumoniae and atherosclerosis: does
study design influence results?. American Heart Journal
2003;145(3):409–17.
Bril 2010
Bril F, Gonzalez CD, Di Girolamo G. Antimicrobial agents-
associated with QT interval prolongation. Current Drug
Safety 2010;5(1):85–92.
Brodala 2005
Brodala N, Merricks EP, Bellinger DA, Damrongsri D,
Offenbacher S, Beck J, et al. Porphyromonas gingivalis
bacteremia induces coronary and aortic atherosclerosis
in normocholesterolemic and hypercholesterolemic pigs.
Arteriosclerosis, Thrombolysis, and Vascular Biology 2005;25
(7):1446–51.
Brok 2008
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial Sequential
Analysis reveals insufficient information size and potentially
false positive results in many meta-analyses. Journal of
Clinical Epidemiology 2008;61(8):763–9.
Brok 2009
Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently
conclusive meta-analyses may be inconclusive--Trial
Sequential Analysis adjustment of random error risk due
to repetitive testing of accumulating data in apparently
conclusive neonatal meta-analyses. International Journal of
Epidemiology 2009;38(1):287–98.
Burnett 2001
Burnett MS, Gaydos CA, Madico GE, Glad SM, Paigen
B, Quinn TC, et al. Atherosclerosis in apoE knockout
mice infected with multiple pathogens. Journal of Infectious
Diseases 2001;183(2):226–31.
Cannon 2005
Cannon CP, Braunwald E, McCabe CH, Grayston JT,
Muhlestein B, Giugliano RP, et al. Antibiotic treatment of
Chlamydia pneumoniae after acute coronary syndrome.
New England Journal of Medicine 2005;352(16):1646–54.
Cheng 2015
Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng
WT, et al. The role of macrolide antibiotics in increasing
cardiovascular risk. Journal of the American College of
Cardiology 2015;66(20):2173–84.
Chirgwin 1989
Chirgwin K, Roblin PM, Hammerschlag MR. In vitro
susceptibilities of Chlamydia pneumoniae (Chlamydia sp.
strain TWAR). Antimicrobial Agents and Chemotherapy
1989;33(9):1634–5.
10Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dalhoff 2003
Dalhoff A, Shalit I. Immunomodulatory effects of
quinolones. The Lancet Infectious Diseases 2003;3(6):
359–71.
Danesh 1997
Danesh J, Collins R, Peto R. Chronic infections and
coronary heart disease: is there a link?. Lancet 1997;350
(9075):430–6.
Danesh 1998
Danesh J, Peto R. Risk factors for coronary heart disease
and infection with Helicobacter pylori: meta-analysis of 18
studies. BMJ 1998;316(7138):1130–2.
Danesh 2000a
Danesh J, Whincup P, Walker M, Lennon L, Thomson A,
Appleby P, et al. Low grade inflammation and coronary
heart disease: prospective study and updated meta-analyses.
BMJ 2000;321(7255):199–204.
Danesh 2000b
Danesh J, Whincup P, Walker M, Lennon L, Thomson A,
Appleby P, et al. Chlamydia pneumoniae IgG titres and
coronary heart disease: prospective study and meta-analysis.
BMJ 2000;321(7255):208–13.
Danesh 2002
Danesh J, Whincup P, Lewington S, Walker M, Lennon L,
Thomson A, et al. Chlamydia pneumoniae IgA titres and
coronary heart disease: prospective study and meta-analysis.
European Heart Journal 2002;23(5):371–5.
De Boer 2014
De Boer SP, Cheng JM, Range H, Garcia-Garcia HM,
Heo JH, Akkerhuis KM, et al. Antibodies to periodontal
pathogens are associated with coronary plaque remodeling
but not with vulnerability or burden. Atherosclerosis 2014;
237(1):84–91.
Deeks 2017
Deeks JJ, Higgins JPT, Altman DG (editors) on behalf of the
Cochrane Statistical Methods Group. Chapter 9: Analysing
data and undertaking meta-analyses. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS (editors), Cochrane
Handbook for Systematic Reviews of Interventions version
5.2.0 (updated June 2017), Cochrane, 2017. Available from
www.training.cochrane.org/handbook.
DeMets 1987
DeMets DL. Methods for combining randomized clinical
trials: strengths and limitations. Statistics in Medicine 1987;
6(3):341–50.
DerSimonian 1986
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Controlled Clinical Trials 1986;7(3):177–88.
Eckel 2014
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller
N, Hubbard VS, et al. 2013 AHA/ACC guideline on
lifestyle management to reduce cardiovascular risk: a report
of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Circulation
2014;129(25 Suppl 2):S76–99.
Egger 1997
Egger M, Davey-Smith G, Schneider M, Minder C. Bias
in meta-analysis detected by a simple, graphical test. BMJ
1997;315(7109):629–34.
Elbourne 2002
Elbourne DR, Altman DG, Higgins JP, Curtin F,
Worthington HV, Vail A. Meta-analyses involving cross-
over trials: methodological issues. International Journal of
Epidemiology 2002;31(1):140–9.
Etminan 2004
Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide
therapy for Chlamydia pneumoniae in the secondary
prevention of coronary artery disease: a meta-analysis of
randomized controlled trials. Pharmacotherapy 2004;24(3):
338–43.
Ezzahiri 2002
Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA, Stassen FR,
Vliegen I, Grauls GE, et al. Chlamydophila pneumoniae
(Chlamydia pneumoniae) accelerates the formation of
complex atherosclerotic lesions in Apo E3-Leiden mice.
Cardiovascular Research 2002;56(2):269–76.
Ezzahiri 2003
Ezzahiri R, Stassen FR, Kurvers HA, Van Pul MM, Kitslaar
PJ, Bruggeman CA. Chlamydia pneumoniae infection
induces an unstable atherosclerotic plaque phenotype in
LDL-receptor, ApoE double knockout mice. European
Journal of Vascular and Endovascular Surgery 2003;26(1):
88–95.
Ferreira-Gonzalez 2014
Ferreira-Gonzalez I. The epidemiology of coronary heart
disease. Revista Espanola de Cardiologia (English Edition)
2014;67(2):139–44.
Fihn 2012
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC,
Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/
SCAI/STS Guideline for the diagnosis and management
of patients with stable ischemic heart disease: a report of
the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines, and
the American College of Physicians, American Association
for Thoracic Surgery, Preventive Cardiovascular Nurses
Association, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons. Journal of
the American College of Cardiology 2012;60(24):e44–e164.
Filardo 2015
Filardo S, Di Pietro M, Farcomeni A, Schiavoni G, Sessa
R. Chlamydia pneumoniae-mediated inflammation in
atherosclerosis: a meta-analysis. Mediators of Inflammation
2015;2015:378658.
Folsom 1998
Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY.
Helicobacter pylori seropositivity and coronary heart disease
incidence. Atherosclerosis Risk In Communities (ARIC)
Study Investigators. Circulation 1998;98(9):845–50.
11Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gaetti-Jardim 2009
Gaetti-Jardim E Jr, Marcelino SL, Feitosa AC, Romito
GA, Avila-Campos MJ. Quantitative detection of
periodontopathic bacteria in atherosclerotic plaques from
coronary arteries. Journal of Medical Microbiology 2009;58
(Pt 12):1568–75.
Gaynor 2003
Gaynor M, Mankin AS. Macrolide antibiotics: binding
site, mechanism of action, resistance. Current Topics in
Medicinal Chemistry 2003;3(9):949–61.
Gluud 2006
Gluud LL. Bias in clinical intervention research. American
Journal of Epidemiology 2006;163(6):493–501.
Gluud 2008
Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen
J, Hansen S, Helø OH, et al. CLARICOR Trial Group.
Clarithromycin for 2 weeks for stable coronary heart disease:
6-year follow-up of the CLARICOR randomized trial and
updated meta-analysis of antibiotics for coronary heart
disease. Cardiology 2008;111(4):280–7.
Gotsman 2007
Gotsman I, Lotan C, Soskolne WA, Rassovsky S, Pugatsch
T, Lapidus L, et al. Periodontal destruction is associated
with coronary artery disease and periodontal infection with
acute coronary syndrome. Journal of Periodontology 2007;
78(5):849–58.
GRADEpro GDT 2015 [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Version accessed 10 August 2015.
Hamilton (ON): McMaster University (developed by
Evidence Prime), 2015.
Grayston 2005
Grayston JT, Kronmal RA, Jackson LA, Parisi AF,
Muhlestein JB, Cohen JD, et al. Azithromycin for the
secondary prevention of coronary events. New England
Journal of Medicine 2005;352(16):1637–45.
Gupta 1997
Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski
JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies,
cardiovascular events, and azithromycin in male survivors of
myocardial infarction. Circulation 1997;96(2):404–7.
Gurfinkel 1999
Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B,
Mautner B. Treatment with the antibiotic roxithromycin in
patients with acute non-Q-wave coronary syndromes. The
final report of the ROXIS Study. European Heart Journal
1999;20(2):121–7.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE: an emerging consensus on
rating quality of evidence and strength of recommendations.
BMJ 2008;336(7650):924–6.
Guyatt 2011
Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P,
Knottnerus A. GRADE guidelines: a new series of articles
in the Journal of Clinical Epidemiology. Journal of Clinical
Epidemiology 2011;64(4):380–2.
Harbord 2006
Harbord RM, Egger M, Sterne JA. A modified test for
small-study effects in meta-analyses of controlled trials
with binary endpoints. Statistics in Medicine 2006;25(20):
3443–57.
Higgins 2002
Higgins JP, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Statistics in Medicine 2002;21(11):1539–58.
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60.
Higgins 2011a
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Higgins 2011b
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2017
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS (editors), Cochrane
Handbook for Systematic Reviews of Interventions version
5.2.0 (updated June 2017), Cochrane, 2017. Available from
www.training.cochrane.org/handbook.
Hizo-Abes 2013
Hizo-Abes P, Clark WF, Sontrop JM, Young A, Huang
A, Thiessen-Philbrook H, et al. Cardiovascular disease
after Escherichia coli O157:H7 gastroenteritis. Canadian
Medical Association Journal 2013;185(1):E70–7.
ICH-GCP 1997
ICH-GCP. 1997 CFR & ICH Guidelines. International
conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use. ICH
harmonised tripartite guideline. Guideline for good clinical
practice. 1. Vol. 1, PA 19063-2043, USA: Barnett
International/PAREXEL, 1997.
Imberger 2015
Imberger G, Gluud C, Boylan J, Wetterslev J. Systematic
reviews of anesthesiologic interventions reported as
statistically significant: problems with power, precision, and
type 1 error protection. Anesthesia & Analgesia 2015;121
(6):1611–22.
Imberger 2016
Imberger G, Thorlund K, Gluud C, Wetterslev J. False-
positive findings in Cochrane meta-analyses with and
12Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
without application of Trial Sequential Analysis: an
empirical review. BMJ Open 2016;6(8):e011890.
Jakobsen 2014
Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud
C. Thresholds for statistical and clinical significance in
systematic reviews with meta-analytic methods. BMC
Medical Research Methodology 2014;14:120.
Jakobsen 2016
Jakobsen JC, Wetterslev J, Lange T, Gluud C. Viewpoint:
taking into account risks of random errors when analysing
multiple outcomes in systematic reviews. Cochrane Database
of Systematic Reviews 2016;3:Ed000111.
Jensen 2010
Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen
JF, Hansen S, et al. Statin treatment prevents increased
cardiovascular and all-cause mortality associated with
clarithromycin in patients with stable coronary heart disease.
Journal of Cardiovascular Pharmacology 2010;55(2):123–8.
Jespersen 2006
Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF,
Hansen S, Helo OH, et al. Randomised placebo controlled
multicentre trial to assess short term clarithromycin for
patients with stable coronary heart disease: CLARICOR
trial. BMJ 2006;332(7532):22–7.
Jiang 2017
Jiang J, Chen Y, Shi J, Song C, Zhang J, Wang K.
Population attributable burden of Helicobacter pylori-
related gastric cancer, coronary heart disease, and ischemic
stroke in China. European Journal of Clinical Microbiology
& Infectious Diseases 2017;36(2):199–212.
Jin 2007
Jin SW, Her SH, Lee JM, Yoon HJ, Moon SJ, Kim PJ, et
al. The association between current Helicobacter pylori
infection and coronary artery disease. Korean Journal of
Internal Medicine 2007;22(3):152–6.
Kaptoge 2010
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB,
Thompson SG, Collins R, et al. C-reactive protein
concentration and risk of coronary heart disease, stroke, and
mortality: an individual participant meta-analysis. Lancet
2010;375(9709):132–40.
Kazar 2005
Kazar J, Kovacova E, Koncova K, Cvachova S, Mongiellova
V, Lietava J, et al. Chlamydia pneumoniae antibodies and
markers of inflammation in patients with cardiovascular
diseases. Bratislavské Lekárske Listy 2005;106(11):341–4.
Keus 2010
Keus F, Wetterslev J, Gluud C, Van Laarhoven CJ. Evidence
at a glance: error matrix approach for overviewing available
evidence. BMC Medical Research Methodology 2010;10(90):
1–14.
Kjaergard 2001
Kjaergard LL, Villumsen J, Gluud C. Reported
methodological quality and discrepancies between small and
large randomized trials in meta-analyses. Annals of Internal
Medicine 2001;135:982–9.
Kuo 1993
Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of
Chlamydia pneumoniae in aortic lesions of atherosclerosis
by immunocytochemical stain. Arteriosclerosis and
Thrombosis 1993;13(10):1501–4.
Lawson 2016
Lawson JS. Multiple Infectious Agents and the Origins
of Atherosclerotic Coronary Artery Disease. Frontiers in
Cardiovascular Medicine 2016;3:30.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Lenzi 2006
Lenzi C, Palazzuoli A, Giordano N, Alegente G,
Gonnelli C, Campagna MS, et al. H pylori infection and
systemic antibodies to CagA and heat shock protein 60
in patients with coronary heart disease. World Journal of
Gastroenterology 2006;12(48):7815–20.
Libby 2002
Libby P, Ridker PM, Maseri A. Inflammation and
atherosclerosis. Circulation 2002;105(9):1135–43.
Libby 2010
Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation
in atherosclerosis: transition from theory to practice.
Circulation Journal 2010;74(2):213–20.
Libby 2011
Libby P, Ridker PM, Hansson GK. Progress and challenges
in translating the biology of atherosclerosis. Nature 2011;
473(7347):317–25.
Linnanmaki 1993
Linnanmaki E, Leinonen M, Mattila K, Nieminen MS,
Valtonen V, Saikku P. Chlamydia pneumoniae-specific
circulating immune complexes in patients with chronic
coronary heart disease. Circulation 1993;87(4):1130–4.
Lundh 2017
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry
sponsorship and research outcome. Cochrane Database of
Systematic Reviews 2017;2:Mr000033.
Maekawa 2011
Maekawa T, Takahashi N, Tabeta K, Aoki Y, Miyashita
H, Miyauchi S, et al. Chronic oral infection with
Porphyromonas gingivalis accelerates atheroma formation
by shifting the lipid profile. PLoS One 2011;6(5):e20240.
Mahdi 2002
Mahdi OS, Horne BD, Mullen K, Muhlestein JB, Byrne GI.
Serum immunoglobulin G antibodies to chlamydial heat
shock protein 60 but not to human and bacterial homologs
are associated with coronary artery disease. Circulation
2002;106(13):1659–63.
Mahendra 2009
Mahendra J, Mahendra L, Kurian VM, Jaishankar K,
Mythilli R. Prevalence of periodontal pathogens in coronary
13Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
atherosclerotic plaque of patients undergoing coronary
artery bypass graft surgery. Journal of Maxillofacial and Oral
Surgery 2009;8(2):108–13.
Mahendra 2015
Mahendra J, Mahendra L, Nagarajan A, Mathew K.
Prevalence of eight putative periodontal pathogens in
atherosclerotic plaque of coronary artery disease patients
and comparing them with noncardiac subjects: a case-
control study. Indian Journal of Dental Research 2015;26(2):
189–95.
Malfertheiner 2007
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F,
El-Omar E, Graham D, et al. Current concepts in
the management of Helicobacter pylori infection: the
Maastricht III Consensus Report. Gut 2007;56(6):772–81.
Matusiak 2016
Matusiak A, Chalubinski M, Broncel M, Rechcinski T,
Rudnicka K, Miszczyk E, et al. Putative consequences
of exposure to Helicobacter pylori infection in patients
with coronary heart disease in terms of humoral immune
response and inflammation. Archives of Medical Science
2016;12(1):45–54.
Mendall 1994
Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T,
Strachan D, et al. Relation of Helicobacter pylori infection
and coronary heart disease. British Heart Journal 1994;71
(5):437–9.
Mendall 1996
Mendall MA, Patel P, Ballam L, Strachan D, Northfield
TC. C reactive protein and its relation to cardiovascular
risk factors: a population based cross sectional study. BMJ
1996;312(7038):1061–5.
Moher 1998
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher
M, et al. Does quality of reports of randomised trials affect
estimates of intervention efficacy reported in meta-analyses?
. Lancet 1998;352(9128):609–13.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA
Group. Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement. Journal of Clinical
Epidemiology 2009;62(10):1006–12.
Montalescot 2013
Montalescot G, Sechtem U, Achenbach S, Andreotti F,
Arden C, Buday A, et al. 2013 ESC guidelines on the
management of stable coronary artery disease: the Task
Force on the management of stable coronary artery disease
of the European Society of Cardiology. European Heart
Journal 2013; Vol. 34, issue 38:2949–3003.
Mozaffarian 2016
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,
Cushman M, et al. Heart Disease and Stroke Statistics-2016
Update: a report from the American Heart Association.
Circulation 2016;133(4):e38–360.
Muhlestein 1996
Muhlestein JB, Hammond EH, Carlquist JF, Radicke E,
Thomson MJ, Karagounis LA, et al. Increased incidence of
Chlamydia species within the coronary arteries of patients
with symptomatic atherosclerotic versus other forms of
cardiovascular disease. Journal of the American College of
Cardiology 1996;27(7):1555–61.
Norman 2003
Norman GR, Sloan JA, Wyrwich KW. Interpretation of
changes in health-related quality of life: the remarkable
universality of half a standard deviation. Medical Care 2003;
41(5):582–92.
Pesonen 2009
Pesonen E, El-Segaier M, Persson K, Puolakkainen M, Sarna
S, Ohlin H, et al. Infections as a stimulus for coronary
occlusion, obstruction, or acute coronary syndromes.
Therapeutic Advances in Cardiovascular Diseases 2009;3(6):
447–54.
Piepoli 2016
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons
C, Catapano AL, et al. 2016 European Guidelines on
cardiovascular disease prevention in clinical practice: the
Sixth Joint Task Force of the European Society of Cardiology
and Other Societies on Cardiovascular Disease Prevention
in Clinical Practice (constituted by representatives of 10
societies and by invited experts). Developed with the special
contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). European Heart
Journal 2016;37(29):2315–81.
Pigarevskii 2015
Pigarevskii PV, Mal’tseva SV, Snegova VA, Davydova
NG, Guseva VA. Chlamydia pneumoniae and
immunoinflammatory reactions in an unstable
atherosclerotic plaque in humans. Bulletin of Experimental
Biology and Medicine 2015;159(2):278–81.
Polk 1999
Polk R. Optimal use of modern antibiotics: emerging
trends. Clinical Infectious Diseases 1999;29(2):264–74.
Prasad 2002
Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein
SE, Quyyumi AA. Predisposition to atherosclerosis by
infections: role of endothelial dysfunction. Circulation
2002;106(2):184–90.
Pucar 2007
Pucar A, Milasin J, Lekovic V, Vukadinovic M, Ristic
M, Putnik S, et al. Correlation between atherosclerosis
and periodontal putative pathogenic bacterial infections
in coronary and internal mammary arteries. Journal of
Periodontology 2007;78(4):677–82.
Pussinen 2004
Pussinen PJ, Alfthan G, Tuomilehto J, Asikainen S,
Jousilahti P. High serum antibody levels to Porphyromonas
gingivalis predict myocardial infarction. European Journal
of Cardiovascular Prevention and Rehabilitation 2004;11(5):
408–11.
14Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rajagopalan 1996
Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis
ZS. Reactive oxygen species produced by macrophage-
derived foam cells regulate the activity of vascular matrix
metalloproteinases in vitro. Implications for atherosclerotic
plaque stability. Journal of Clinical Investigation 1996;98
(11):2572–9.
Renvert 2006
Renvert S, Pettersson T, Ohlsson O, Persson GR. Bacterial
profile and burden of periodontal infection in subjects
with a diagnosis of acute coronary syndrome. Journal of
Periodontology 2006;77(7):1110–9.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Ridker 1999
Ridker PM, Kundsin RB, Stampfer MJ, Poulin S,
Hennekens CH. Prospective study of Chlamydia
pneumoniae IgG seropositivity and risks of future
myocardial infarction. Circulation 1999;99(9):1161–4.
Roivainen 2000
Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P,
Leinonen M, Saikku P, et al. Infections, inflammation, and
the risk of coronary heart disease. Circulation 2000;101(3):
252–7.
Romano Carratelli 2006
Romano Carratelli C, Nuzzo I, Cozzolino D, Bentivoglio
C, Paolillo R, Rizzo A. Relationship between Chlamydia
pneumoniae infection, inflammatory markers, and coronary
heart diseases. International Immunopharmacology 2006;6
(5):848–53.
Rosenfeld 2011
Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis:
update on the potential contribution of multiple infectious
organisms to the pathogenesis of atherosclerosis. Thrombosis
and Haemostasis 2011;106(5):858–67.
Ross 1999
Ross R. Atherosclerosis--an inflammatory disease. NEJM
1999;340(2):115–26.
Saikku 1988
Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen
MS, Makela PH, et al. Serological evidence of an association
of a novel Chlamydia, TWAR, with chronic coronary heart
disease and acute myocardial infarction. Lancet 1988;2
(8618):983–6.
Sakurai-Komada 2014
Sakurai-Komada N, Iso H, Koike KA, Ikeda A, Umesawa
M, Ikehara S, et al. Association between Chlamydophila
pneumoniae infection and risk of coronary heart disease
for Japanese: the JPHC study. Atherosclerosis 2014;233(2):
338–42.
Sapadin 2006
Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic
properties and their clinical implications. Journal of the
American Academy of Dermatology 2006;54(2):258–65.
Savovic 2012
Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal
J, et al. Influence of reported study design characteristics on
intervention effect estimates from randomized, controlled
trials. Annals of Internal Medicine 2012;157(6):429–38.
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273(5):408–12.
Schunemann 2003
Schunemann HJ, Best D, Vist G, Oxman AD. Letters,
numbers, symbols and words: how to communicate grades
of evidence and recommendations. Canadian Medical
Association Journal 2003;169(7):677–80.
Schunemann 2013
Schunemann HJ, Brozek J, Guyatt G, Oxman AD,
editors. GRADE handbook for grading quality of
evidence and strength of recommendation. Available
from http://gdt.guidelinedevelopment.org/app/handbook/
handbook.html. The Grade Working Group 2013.
Schünemann 2017
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks
JJ, Glasziou P, Akl E, Guyatt GH on behalf of the Cochrane
Applicability and Recommendations Methods Group.
Chapter 12: Interpreting results and drawing conclusions.
In: Higgins JPT, Churchill R, Chandler J, Cumpston MS
(editors), Cochrane Handbook for Systematic Reviews of
Interventions version 5.2.0 (updated June 2017). Cochrane,
2017. Available from www.training.cochrane.org/
handbook.
Shmuely 2014
Shmuely H, Wattad M, Solodky A, Yahav J, Samra Z, Zafrir
N. Association of Helicobacter pylori with coronary artery
disease and myocardial infarction assessed by myocardial
perfusion imaging. Israel Medicine Association Journal 2014;
16(6):341–6.
Shor 1992
Shor A, Kuo CC, Patton DL. Detection of Chlamydia
pneumoniae in coronary arterial fatty streaks and
atheromatous plaques. South African Medical Journal 1992;
82(3):158–61.
Smith 2011
Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager
MA, Franklin BA, et al. AHA/ACCF secondary prevention
and risk reduction therapy for patients with coronary
and other atherosclerotic vascular disease: 2011 update:
a guideline from the American Heart Association and
American College of Cardiology Foundation endorsed
by the World Heart Federation and the Preventive
Cardiovascular Nurses Association. Journal of the American
College of Cardiology 2011;58(23):2432–46.
15Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Spahr 2006
Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche
R, Kunze M, et al. Periodontal infections and coronary
heart disease: role of periodontal bacteria and importance
of total pathogen burden in the Coronary Event and
Periodontal Disease (CORODONT) study. Archives of
Internal Medicine 2006;166(5):554–9.
Steel 2012
Steel HC, Theron AJ, Cockeran R, Anderson R, Charles F.
Pathogen- and host-directed anti-inflammatory activities of
macrolide antibiotics. Mediators of Inflammation 2012.
Sun 2016
Sun J, Rangan P, Bhat SS, Liu L. A meta-analysis of the
association between Helicobacter pylori infection and risk of
coronary heart disease from published prospective studies.
Helicobacter 2016;21(1):11–23.
Thom 1991
Thom DH, Wang SP, Grayston JT, Siscovick DS, Stewart
DK, Kronmal RA, et al. Chlamydia pneumoniae strain
TWAR antibody and angiographically demonstrated
coronary artery disease. Arteriosclerosis and Thrombosis
1991;11(3):547–51.
Thorlund 2009
Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G,
Ioannidis JP, Thabane L, et al. Can trial sequential
monitoring boundaries reduce spurious inferences from
meta-analyses?. International Journal of Epidemiology 2009;
38(1):276–86.
Thorlund 2010
Thorlund K, Anema A, Mills E. Interpreting meta-analysis
according to the adequacy of sample size. An example using
isoniazid chemoprophylaxis for tuberculosis in purified
protein derivative negative HIV-infected individuals.
Journal of Clinical Epidemiology 2010;2:57–66.
Thorlund 2011
Thorlund K, Imberger G, Walsh M, Chu R, Gluud C,
Wetterslev J, et al. The number of patients and events
required to limit the risk of overestimation of intervention
effects in meta-analysis - a simulation study. PLoS One
2011;6(10):e25491.
Torgano 1999
Torgano G, Cosentini R, Mandelli C, Perondi R, Blasi F,
Bertinieri G, et al. Treatment of Helicobacter pylori and
Chlamydia pneumoniae infections decreases fibrinogen
plasma level in patients with ischemic heart disease.
Circulation 1999;99(12):1555–9.
TSA 2011 [Computer program]
Copenhagen Trial Unit. Trial Sequential Analysis. Version
0.9 beta. Copenhagen: Copenhagen Trial Unit, 2011.
Turner 2013
Turner RM, Bird SM, Higgins JP. The impact of study size
on meta-analyses: examination of underpowered studies in
Cochrane reviews. PLoS One 2013;8(3):e59202.
Vcev 2007
Vcev A, Nakic D, Mrden A, Mirat J, Balen S, Ruzic A, et al.
Helicobacter pylori infection and coronary artery disease.
Collegium Antropologicum 2007;31(3):757–60.
Waksman 1947
Waksman SA. What is an antibiotic or an antibiotic
substance?. Mycologia 1947;39(5):565–9.
Wetterslev 2008
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential
analysis may establish when firm evidence is reached in
cumulative meta analysis. Journal of Clinical Epidemiology
2008;61:64–75.
Wetterslev 2009
Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating
required information size by quantifying diversity in
random-effects model meta-analyses. BMCMedical Research
Methodology 2009;9:86.
Wetterslev 2017
Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential
Analysis in systematic reviews with meta-analysis. BMC
Medical Research Methodology 2017;17(1):39.
Whincup 1996
Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker
M. Prospective relations between Helicobacter pylori
infection, coronary heart disease, and stroke in middle aged
men. Heart 1996;75(6):568–72.
WHO 2011
Mendis S, Puska P, Norrving B (editors). Global Atlas on
Cardiovascular Disease Prevention and Control. Geneva:
World Health Organization, 2011.
WHO 2016
World Health organization. Cardiovascular diseases - Fact
sheet N 317. WHO - Available from: www.who.int/
mediacentre/factsheets/fs317/en/ Updated 2016 Jun; cited
2016 Aug 20].
Winkel 2011
Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P,
Kastrup J, Kolmos HJ, et al. Excess sudden cardiac deaths
after short-term clarithromycin administration in the
CLARICOR trial: why is this so, and why are statins
protective?. Cardiology 2011;118(1):63–7.
Winkel 2015
Winkel P, Hilden J, Hansen JF, Kastrup J, Kolmos HJ,
Kjoller E, et al. Clarithromycin for stable coronary heart
disease increases all-cause and cardiovascular mortality and
cerebrovascular morbidity over 10 years in the CLARICOR
randomised, blinded clinical trial. International Journal of
Cardiology 2015;182:459–65.
Wong 2014
Wong ND. Epidemiological studies of CHD and the
evolution of preventive cardiology. Nature Reviews
Cardiology 2014;11(5):276–89.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
16Antibiotics for secondary prevention of coronary heart disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ 2008;336
(7644):601–5.
Zaremba 2007
Zaremba M, Gorska R, Suwalski P, Kowalski J. Evaluation
of the incidence of periodontitis-associated bacteria in the
atherosclerotic plaque of coronary blood vessels. Journal of
Periodontology 2007;78(2):322–7.
Zhu 2001
Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB,
Epstein SE. Prospective study of pathogen burden and risk
of myocardial infarction or death. Circulation 2001;103(1):
45–51.
Zhu 2002
Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD,
Zalles-Ganley A, et al. Lack of association of Helicobacter
pylori infection with coronary artery disease and frequency
of acute myocardial infarction or death. American Journal of
Cardiology 2002;89(2):155–8.
∗ Indicates the major publication for the study
A D D I T I O N A L T A B L E S
Table 1. The Cochrane tool for assessing risk of bias
Domain Description
Random sequence generation • Low risk: if sequence generation was achieved using computer random number
generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were also considered adequate if performed by an independent
adjudicator.
• Unclear risk: if the method of randomisation was not specified, but the trial was
still presented as being randomised.
• High risk: if the allocation sequence was not randomised or only quasi-
randomised. We will exclude these trials.
Allocation concealment • Low risk: if the allocation of participants was performed by a central independent
unit, on-site locked computer, identical-looking numbered sealed envelopes, drug
bottles, or containers prepared by an independent pharmacist or investigator.
• Uncertain risk: if the trial was classified as randomised but the allocation
concealment process was not described.
• High risk: if the allocation sequence was familiar to the investigators who assigned
participants.
Blinding of participants and personnel • Low risk: if the participants and the personnel were blinded to intervention
allocation and this was described.
• Uncertain risk: if the procedure of blinding was insufficiently described.
• High risk: if blinding of participants and the personnel was not performed.
Blinding of outcome assessment • Low risk of bias: if it was mentioned that outcome assessors were blinded and this
was described.
• Uncertain risk of bias: if it was not mentioned if the outcome assessors in the trial
were blinded, or the extent of blinding was insufficiently described.
• High risk of bias: if no blinding or incomplete blinding of outcome assessors was
performed.
Incomplete outcome data • Low risk of bias: if missing data were unlikely to make treatment effects depart
from plausible values. This could either be: 1) there were no drop-outs or withdrawals
for all outcomes, or 2) the numbers and reasons for the withdrawals and drop-outs for
all outcomes were clearly stated and could be described as being similar in both groups.
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Table 1. The Cochrane tool for assessing risk of bias (Continued)
Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if
drop-outs are less than 5%. However, the 5% cut-off is not definitive.
• Uncertain risk of bias: if there was insufficient information to assess whether
missing data were likely to induce bias on the results.
• High risk of bias: if the results were likely to be biased due to missing data either
because the pattern of drop-outs could be described as being different in the two
intervention groups or the trial used improper methods in dealing with the missing
data (e.g. last observation carried forward).
Selective outcome reporting • Low risk of bias: if a protocol was published before or at the time the trial was
begun and the outcomes specified in the protocol were reported on. If there is no
protocol or the protocol was published after the trial has begun, reporting of all-cause
mortality and serious adverse events will grant the trial a grade of low risk of bias.
• Uncertain risk of bias: if no protocol was published and the outcomes all-cause
mortality and serious adverse events were not reported on.
• High risk of bias: if the outcomes in the protocol were not reported on.
Other risks of bias • Low risk of bias: if the trial appears to be free of other components (for example,
academic bias or for-profit bias) that could put it at risk of bias.
• Unclear risk of bias: if the trial may or may not be free of other components that
could put it at risk of bias.
• High risk of bias: if there are other factors in the trial that could put it at risk of
bias (for example, authors have conducted trials on the same topic, for-profit bias etc).
Overall risk of bias • Low risk of bias: the trial will be classified as overall ’low risk of bias’ only if all of
the bias domains described in the above paragraphs are classified as ’low risk of bias’.
• High risk of bias: the outcome result will be classified ’high risk of bias’ if any of the
bias risk domains described in the above are classified as ’unclear’ or ’high risk of bias’.
A P P E N D I C E S
Appendix 1. MEDLINE preliminary search strategy
1. exp Coronary Disease/
2. exp Myocardial Ischemia/
3. (myocard* adj3 infarct*).tw.
4. (coronary adj3 disease*).tw.
5. (myocard* adj3 ischemi*).tw.
6. (myocard* adj3 ischaem*).tw.
7. (ischemic adj3 heart).tw.
8. (ischaemic adj3 heart).tw.
9. exp Atherosclerosis/
10. atheroscleropenici*.tw.
11. angina*.tw.
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12. or/1-11
13. Anti-Bacterial Agents/
14. Penicillin*.tw.
15. cephalosporin*.tw.
16. carbapenem*.tw.
17. monobactam*.tw.
18. beta-lactam*.tw.
19. aminoglycoside*.tw.
20. macrolide*.tw.
21. clindamycin*.tw.
22. exp Penicillins/
23. exp lactams/ or beta-lactams/
24. exp Tetracyclines/
25. exp Aminoglycosides/
26. exp Macrolides/
27. exp Clindamycin/
28. exp Chloramphenicol/
29. Fusidic Acid/
30. Vancomycin/
31. Daptomycin/
32. exp Polymyxins/
33. (antibiotic* or anti-bacterial* or anti-infective*).tw.
34. or/13-33
35. 12 and 34
36. randomized controlled trial.pt.
37. controlled clinical trial.pt.
38. randomized.ab.
39. placebo.ab.
40. drug therapy.fs.
41. randomly.ab.
42. trial.ab.
43. groups.ab.
44. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
45. exp animals/ not humans.sh.
46. 44 not 45
47. 35 and 46
WH A T ’ S N E W
Date Event Description
12 July 2017 New citation required and major changes Authorship changedwith newauthor andnewcontact person.Themeth-
ods have been updated in line with more recent Collaboration guidelines
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